News
Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years
Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis have demonstrated laboratory safety during dupilumab treatment. The randomized study presented below supplements the data for the age group from 6 months to 6 years.
Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It…
How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?
Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2…
Prof. Roman Chlíbek: Role of Multivalent Pneumococcal Conjugate Vaccines in Healthy and Premature Children
Children are frequent carriers of pneumococci, which can cause both common non-invasive and more…
Hereditary Angioedema as a Clinical Picture of Excessive Activation of the Kinin Cascade – Case Report
Painful and potentially life-threatening swellings are characteristic of hereditary angioedema…
Efficacy of Empagliflozin in HFpEF Patients – Comparison of Subpopulations with Preserved and Mid-Range LV EF
A sub-analysis of the EMPEROR-Preserved clinical trial examined the effects and safety of…
EULAR 2023: How does tofacitinib affect cardiovascular risk in rheumatoid arthritis?
At this year's European League Against Rheumatism (EULAR) congress, held at the turn of May and…
Efficacy of Ceftazidime/Avibactam in the Treatment of Infections Caused by Carbapenemase-Producing Enterobacteria
Infections caused by carbapenemase-producing enterobacteria are associated with high mortality, and…
EULAR 2023: What Do CRP Levels Reveal About the Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis?
What is the impact of baseline C-reactive protein (CRP) levels on the efficacy and safety of…
Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based on…
Popular this week
- Where did COVID come from? Are infected animals or a lab leak to blame for the pandemic?
- New Algorithm to Enhance Prediction of Cardiovascular Disease Risk
- Influence of some anesthetics and sedatives on source of sexual hallucination: undervalued forensic risk for doctors
- Target blood pressure values in heart failure
- Using propofol − what is forbidden, is not (really) allowed ... or what are we risking if we use it in contradiction with the SPC?